Acesol - instructions for use, doses, side effects, contraindications

Active substancePotassium chloride + Sodium acetate + Sodium chloridePotassium chloride + Sodium acetate + Sodium chloride

Similar drugsTo uncover

Acesol

solution in / in

BIOSINTEZ, PAO Russia

Acesol

solution in / in

MOSFARM, LLC

Acesol

solution d / infusion

KRASFARMA, JSC Russia

Acesol

solution d / infusion

Kursk Biofactory - BIOK, FKP Russia

Acesol

solution d / infusion

GROTEKS, LLC Russia

Acesol

solution d / infusion

RESTER, CJSC Russia

Acesol

solution d / infusion

GEMATEK, LLC Russia

Acesol

solution d / infusion

ESKOM NPK, OAO Russia

Acesol

solution d / infusion

DALHIMFARM, OJSC Russia

Acesol

solution d / infusion

NESVIZH FACTORY OF MEDICAL PREPARATIONS, RUP Republic of Belarus

Chlossol

solution in / in

BIOCHEMIST, OJSC Russia

Chlossol

solution in / in

GROTEKS, LLC Russia

Chlossol

solution in / in

NESVIZH FACTORY OF MEDICAL PREPARATIONS, RUP Republic of Belarus

Dosage form: & nbspsolution for infusions

Composition:

Composition per one liter:

Active substances:

Sodium chloride - 5 g

Sodium acetate trihydrate (sodium acetate, 3-water) - 2 g

Potassium chloride -1 g

Excipients:

Water for injections - up to 1 liter

Ionic composition: in 1 liter of the drug contains:

Sodium-ion -100.3 mmol

Potassium ion -13.4 mmol

Chloride-ion - 99.0 mmol

Acetate ion -14.7 mmol

Theoretical osmolality - 227.4 mOsm / l

Description:Transparent colorless liquid.

Pharmacotherapeutic group:Rehydrating agent

ATX: & nbsp

B.05.B.B.01 Electrolytes

Pharmacodynamics:

Combined drug, has detoxification, plasma-substituting, rehydrating, diuretic, anti-shock, antiaggregant effect. It reduces hypovolemia, prevents blood clotting and the development of metabolic acidosis, increases diuresis, improves microcirculation.

Pharmacokinetics:

K + ions Na + short-lived in the vascular bed, quickly distributed to all tissues of the body. Excreted mainly by the kidneys, in small amounts - through the intestine, then, with tears, etc.

In the body, acetate is activated in acetyl-coenzyme A, then the main amount of active acetate is completely oxidized in the Krebs cycle to carbon dioxide and water. The oxidation of acetate is carried out in muscle cells, so the ability of the body to metabolize it is largely dependent on the muscle mass of the body. Metabolism of acetyl-CoA can also go along a small pathway of oxidation with the formation of fatty acids, keto acids and cholesterol.

Indications:

Dehydration, intoxication (acute shigellosis, food poisoning, cholera).

Contraindications:

Hypersensitivity, hyperkalemia, alkalosis, chronic renal failure, the presence of contraindications to the introduction of large quantities of liquid into the body.

Carefully:In patients with impaired renal excretory function.

Pregnancy and lactation:

Perhaps, if the expected effect of therapy in the mother exceeds the potential risk for the fetus and the child (adequate and strictly controlled safety studies in pregnant and lactating women were not performed).

Dosing and Administration:

The drug is used only for moderate and severe conditions when it is impossible to take solutions for oral rehydration, injected intravenously into the jet (1-3 h).

Before administration, the solution is heated to 36-38 ° C. The volume of the solution to be administered is selected individually, in an amount necessary to restore the water-electrolyte balance (in severe forms of the disease for 1 hour, inject the solution in an amount corresponding to 7-10% of the body weight of the patient, then the jet injection is replaced with a drop, at a rate of 40-120 cap / min (24-48 h)), under the control of laboratory indicators. The balance of injected and lost fluid is determined every 6 hours.The total amount of the solution administered should correspond to the volume of the liquid excreted in the excreta, vomit, urine and sweat.

Side effects:Edema, tachycardia, chills, hyperkalemia.

Overdose:

Symptoms. In patients with chronic kidney disease or with any disease accompanied by a violation of the excretion of potassium from the body, or with too rapid IV introduction of the drug may develop hyperkalemia, which could potentially lead to death. Early clinical manifestations of hyperkalemia (taper P, tooth extinction U, segmentation ST and lengthening the interval QT) usually appear at a serum potassium concentration of 7 to 8 meq / L. More severe symptoms (including muscle paralysis and cardiac arrest) develop at a potassium concentration of 9-10 meq / L. It should be borne in mind that hyperkalemia, leading to death, can develop rapidly and proceed asymptomatically.

Treatment: cancellation of the drug, with the phenomena of hyperkalemia - the drug is replaced with a solution of "Disol" until the electrolyte balance is normalized. If necessary, hemodialysis and peritoneal dialysis are performed.

Interaction:If necessary, a combination with an infusion of blood, plasma, polyglucin, etc. is possible.

Special instructions:

Treatment is carried out under the control of hematocrit and the concentration of electrolytes of blood.

In the case of hyperkalemia, the drug is replaced with a solution of "Disol" until the electrolyte balance is normalized.

Studies to evaluate the effect of the drug on the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions have not been conducted.

In general, with the dehydration, the introduction of special solutions is shown inside, and only when this is impossible (indomitable vomiting, severe dehydration, severity of general condition, etc.), the drug is administered parenterally.

Effect on the ability to drive transp. cf. and fur:Not described.

Form release / dosage:Solution for infusion.

Packaging:

200 ml or 400 ml in a glass bottle, sealed with rubber stopper and crimped aluminum or combined cap.

1. A bottle with instructions for use is placed in a pack of cardboard.

2. For hospitals.20, 24 bottles of 200 ml or 12 bottles of 400 ml with an equal number of instructions for use, placed in a group box - boxes of cardboard corrugated.

250 ml or 500 ml in a soft polymer container.

1. Each container with instructions for use is packaged in a secondary bag of film, the bag is sealed. It is allowed to apply the text of the instruction for medical use thermographically to a secondary bag (the instruction is not included in the secondary bag).

24 containers of 250 ml or 12 containers of 500 ml, sealed in secondary bags, placed in a group box - boxes of corrugated cardboard.

2. Each container is packed in a secondary bag of film, the bag is sealed. A self-adhesive multi-page label is glued onto the bag.

24 containers of 250 ml or 12 containers of 500 ml, sealed in secondary bags, placed in a group box - boxes of corrugated cardboard.

3. For hospitals. Each container is packed in a secondary bag of film, the bag is sealed.

24 containers of 250 ml or 12 containers of 500 ml sealed in secondary bags, with an equal number of instructions for use, are placed in a group box - boxes of cardboard corrugated.

Storage conditions:

At a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Note:

1 Freezing the drug is not a contraindication to its use.

2. The non-wetting of the inner surface of the bottle or polymer container is not a contraindication to the use of the preparation.

Shelf life:

2 years.

Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:LS-001865

Date of registration:19.12.2011 / 16.05.2014

Expiration Date:Unlimited

The owner of the registration certificate:BIOSINTEZ, PAO BIOSINTEZ, PAO Russia

Manufacturer: & nbsp

BIOSINTEZ, PAO Russia

Information update date: & nbsp29.09.2017

Illustrated instructions

Instructions

Acesol (Acesol)